source
- Sofinnova Partners closes €725 million (≈$815 million) Crossover II fund to back ~15 European clinical-stage biotech firmsSofinnova Partners announced the closing of its largest fund to date, Crossover II, with €725 million (about $815 million) in capital. The fund plans to invest in roughly 15 clinical‑stage compani…
- Bristol Myers Squibb reshuffles R&D leadership as chief research officer departs and CMO takes over combined unitBristol Myers Squibb announced a restructuring of its research and development organization, merging the separate research and development divisions into a single unit. The new combined R&D unit w…